Global /United States /Healthcare /Drug Manufacturers - General /AMPH
chevron_leftBack
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc.

AMPH
NASDAQ: AMPH Delayed
21.61USD -1%
As of 13 June 2026, Amphastar Pharmaceuticals, Inc. has a market cap of $962.18M USD, ranking #10917 globally and #2190 in the United States. It ranks #980 in the Healthcare sector, and #363 in the Drug Manufacturers - General industry.
Global Rank
10917
Country Rank
2190
Sector Rank
980
Industry Rank
363
Key Stats
Market Cap
$962.18MUSD
Enterprise Value
$1.34BUSD
Revenue (TTM)
$719.89MUSD
EBITDA (TTM)
$220.2MUSD
Net Income (TTM)
$98.09MUSD
EBITDA Margin
31%
Profit Margin
14%
PE Ratio
10.6
Forward PE
6.6
PS Ratio
1.3
PB Ratio
1.3
EV/EBITDA
6.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yongfeng Zhang open_in_new
Employees
1,976
Founded
1996
IPO
25 Jun 2014
Website
amphastar.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1% 2.9% 14% -17% -11% -11%

News

Loading...

AMPH Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
AMPH
Amphastar Pharmaceuticals Inc
ISIN: US03209R1032
Shares Out.:
44.093M1 Shares Float: 32.627M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
21.61 USD
Frankfurt Stock Exchange
MIC: XFRA
29A
Amphastar Pharmaceuticals Inc
ISIN: US03209R1032
TV:
SA:
YF:
GF:
BA:
29A
MS:
17.99 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
PE
LLY
$761.68B
79K%
38.1
JNJ
$547.28B
57K%
26.4
ABBV
$360.63B
37K%
97.4
MRK
$274.03B
28K%
15.1
PFE
$149.38B
15K%
19.5
$117.58B
12K%
16.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
$321.52B
256.25B CHF
33K%
19.9
AZN
$288.84B
215.59B GBP
30K%
27.6
NOVN
$274.65B
218.9B CHF
28K%
20.5
NOVO-B
$181.82B
1.18T DKK
19K%
11.5
SAN
$110.1B
95.26B EUR
11K%
19.9
GSK
$108.46B
80.96B GBP
11K%
14.6
chevron_leftBack